Peer-influenced content. Sources you trust. No registration required. This is HCN.
British Journal of Hospital Medicine
Can you differentiate between bradykinin-mediated angioedema and the more common histamine-mediated angioedema? How significant is a delayed diagnosis? Do you favor on-demand or preventative therapy? What is the recommended therapy? Access to specialist care and effective treatment in the past 10 years has improved the quality of life and reduced the mortality rate in patients with hereditary angioedema. This wide-ranging report from the British Journal of Hospital Medicine covers emerging treatments and outlines where we’ve been, where we are, and where we’re going in hereditary angioedema (HAE) care.
Emergency Medicine August 24th 2021
Consultant360
Often undiagnosed due to its unspecific symptoms, hereditary angioedema (HAE) is a tricky condition that causes many patients unnecessary suffering with unnecessary surgeries and invasive diagnostic/therapeutic interventions. Read on to educate yourself on some of the alarming numbers on the orphan disease.
Dermatology August 17th 2021
Journal of Clinical Oncology
Despite aggressive therapy, the 5-year survival rate for patients with metastatic or recurrent rhabdomyosarcoma – the most common soft tissue sarcoma of childhood – remains poor, and beyond PAX-FOX01 fusion status, no genomic markers are available for risk stratification. This international consortium study was designed to determine the incidence of driver mutations and their association with clinical outcome.
Internal Medicine July 6th 2021